Skip to content
Search
Close
Search
Close
Phase 1b study of Bavdegalutamide, an androgen receptor PROTAC® degrader, combined with abiraterone in patients with metastatic prostate cancer
Neal D. Shore, et al.
June 3, 2022
American Society for Clinical Oncology (ASCO)
Download
Search
Close
Our Science
PROTAC® Discovery Engine
Scientific Publications
Partnerships
About Us
Leadership
Board of Directors
Scientific Advisory Board
Research & Development
Pipeline
Androgen Receptor
Estrogen Receptor
Neuroscience
Careers & Culture
Open Positions
Life in New Haven
Our Values
Benefits
Giving Back
Patients
Patients with Breast Cancer
Patients with Prostate Cancer
Clinical Trials
Expanded Access Policy
Investors & Media
Press Releases
Events & Presentations
Corporate Governance
Financials & SEC Filings
Annual Meeting
Stock Information
Analyst Coverage
Investor FAQs
Resources
Email Alerts
Contact Us
Menu
Contact Us
Linkedin-in
Twitter
Skip to content
